AU2018351059B2 - Benzimidazole derivatives and their uses - Google Patents

Benzimidazole derivatives and their uses Download PDF

Info

Publication number
AU2018351059B2
AU2018351059B2 AU2018351059A AU2018351059A AU2018351059B2 AU 2018351059 B2 AU2018351059 B2 AU 2018351059B2 AU 2018351059 A AU2018351059 A AU 2018351059A AU 2018351059 A AU2018351059 A AU 2018351059A AU 2018351059 B2 AU2018351059 B2 AU 2018351059B2
Authority
AU
Australia
Prior art keywords
methyl
benzo
imidazol
amino
fluoropiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018351059A
Other languages
English (en)
Other versions
AU2018351059A1 (en
Inventor
Michael D. Bartberger
Nagasree Chakka
Hua Gao
Angel Guzman-Perez
Daniel B. Horne
Zihao Hua
Madeleine KIEFFER
Daniel C. H. Lin
Benjamin Charles Milgram
Jane PANTELEEV
Laurie Schenkel
John Stellwagen
Matthew Weiss
Ryan D. WHITE
Wei Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AU2018351059A1 publication Critical patent/AU2018351059A1/en
Assigned to TEIJIN PHARMA LIMITED reassignment TEIJIN PHARMA LIMITED Request for Assignment Assignors: AMGEN INC.
Application granted granted Critical
Publication of AU2018351059B2 publication Critical patent/AU2018351059B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018351059A 2017-10-19 2018-10-18 Benzimidazole derivatives and their uses Active AU2018351059B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762574465P 2017-10-19 2017-10-19
US62/574,465 2017-10-19
US201862671090P 2018-05-14 2018-05-14
US62/671,090 2018-05-14
PCT/US2018/056484 WO2019079578A1 (en) 2017-10-19 2018-10-18 BENZIMIDAZOLE DERIVATIVES AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2018351059A1 AU2018351059A1 (en) 2020-04-23
AU2018351059B2 true AU2018351059B2 (en) 2022-05-12

Family

ID=66173507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018351059A Active AU2018351059B2 (en) 2017-10-19 2018-10-18 Benzimidazole derivatives and their uses

Country Status (24)

Country Link
US (1) US11332459B2 (enExample)
EP (1) EP3697410B1 (enExample)
JP (1) JP7450534B2 (enExample)
KR (1) KR102697255B1 (enExample)
CN (1) CN111417394B (enExample)
AU (1) AU2018351059B2 (enExample)
CA (1) CA3079081A1 (enExample)
CL (1) CL2020001020A1 (enExample)
CO (1) CO2020004669A2 (enExample)
ES (1) ES3004333T3 (enExample)
HR (1) HRP20250272T1 (enExample)
HU (1) HUE070649T2 (enExample)
IL (1) IL273839B (enExample)
MA (1) MA50413A (enExample)
MX (1) MX2020003993A (enExample)
NZ (1) NZ763311A (enExample)
PH (1) PH12020550265A1 (enExample)
PL (1) PL3697410T3 (enExample)
SA (1) SA520411787B1 (enExample)
SG (1) SG11202003502VA (enExample)
TW (1) TWI816704B (enExample)
UY (1) UY37941A (enExample)
WO (1) WO2019079578A1 (enExample)
ZA (1) ZA202002762B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112118845B (zh) 2018-05-14 2023-06-13 吉利德科学公司 Mcl-1抑制剂
CN114096247B (zh) 2019-04-11 2024-04-26 帝人制药株式会社 苯并咪唑衍生物及其用途
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
PT4065567T (pt) 2019-11-26 2024-11-08 Gilead Sciences Inc Processos e intermediários para a preparação de inibidores de mcl1
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
CN115379841A (zh) * 2020-04-16 2022-11-22 勃林格殷格翰国际有限公司 治疗呼吸系统病症的trpc6抑制剂
JP7659630B2 (ja) 2020-11-19 2025-04-09 ギリアード サイエンシーズ， インコーポレイテッド 大環状ｍｃｌ１阻害剤を調製するための方法及び中間体
EP4364739A4 (en) * 2021-06-29 2025-06-25 Osaka University Pharmaceutical composition for preventing and/or treating kidney injury, and autophagy activator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106655A1 (en) * 2000-08-10 2004-06-03 Hiroshi Kitajima Proline derivatives and the use thereof as drugs
US20040152690A1 (en) * 2002-10-17 2004-08-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2618435B1 (fr) 1987-07-23 1989-10-27 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
ES2278065T3 (es) 2001-10-15 2007-08-01 Janssen Pharmaceutica N.V. Nuevos derivados de 4-fenil-4-(1h-imidazol-2-il)-piperidina sustituida y su uso como agonistas selectivos de opioides delta no peptidos.
AU2002363369B2 (en) 2001-10-15 2008-08-21 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
WO2004011440A1 (ja) 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
US20070105890A1 (en) * 2003-11-26 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd Novel condensed imidazole derivative
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006010283A1 (en) 2004-07-28 2006-02-02 Universität Zürich Prevention and treatment of thrombus formation
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
US20100267717A1 (en) 2005-07-29 2010-10-21 4Sc Ag Novel Heterocyclic NF-kB Inhibitors
DE102005012875B4 (de) * 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
DE102005012874A1 (de) 2005-03-19 2006-09-21 Sanofi-Aventis Deutschland Gmbh Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE520634T1 (de) * 2005-04-06 2011-09-15 Univ North Carolina State Verfahren zur herstellung von dichten, geformten gegenständen aus einem feuerfesten material
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
CA2625150A1 (en) 2005-10-07 2007-04-19 Waratah Pharmaceuticals, Inc. Combined use of dpp-iv inhibitors and gastrin compounds
WO2008003667A2 (en) 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
MX2009001913A (es) 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2008153701A1 (en) 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
CA2695008A1 (en) 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2009089234A2 (en) 2008-01-07 2009-07-16 Auspex Pharmaceuticals Substituted dibenzhydrylpiperazines
WO2010104306A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
CA2765171C (en) 2009-06-10 2018-10-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2012098281A2 (es) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Péptidos moduladores de receptores trp y sus usos
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP2698367A1 (en) 2012-08-14 2014-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzimidazoles for the treatment of cancer
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
KR102494596B1 (ko) 2014-07-31 2023-01-31 재단법인 한국파스퇴르연구소 2-아미노-벤즈이미다졸 유도체 및 5-리폭시게나아제 및/또는 프로스타글란딘 e 합성효소 억제제로서의 이들의 용도
TW201643138A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶（ｈｄａｃ）抑制劑之３－螺－７－異羥肟酸四氫萘
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
GB201603311D0 (en) 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
US10501421B1 (en) * 2017-01-27 2019-12-10 Vanderbilt University Substituted benzimidazoles as modulators of Ras signaling

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106655A1 (en) * 2000-08-10 2004-06-03 Hiroshi Kitajima Proline derivatives and the use thereof as drugs
US20040152690A1 (en) * 2002-10-17 2004-08-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics

Also Published As

Publication number Publication date
ES3004333T3 (en) 2025-03-12
JP7450534B2 (ja) 2024-03-15
HRP20250272T1 (hr) 2025-04-25
EP3697410A1 (en) 2020-08-26
PL3697410T3 (pl) 2025-04-07
MA50413A (fr) 2020-08-26
CO2020004669A2 (es) 2020-05-05
US20200308145A1 (en) 2020-10-01
KR102697255B1 (ko) 2024-08-23
TW201930284A (zh) 2019-08-01
SG11202003502VA (en) 2020-05-28
BR112020007589A8 (pt) 2022-08-02
BR112020007589A2 (pt) 2020-09-24
TWI816704B (zh) 2023-10-01
JP2021500332A (ja) 2021-01-07
HUE070649T2 (hu) 2025-06-28
CA3079081A1 (en) 2019-04-25
EP3697410B1 (en) 2024-12-18
UY37941A (es) 2019-04-30
CN111417394B (zh) 2023-11-07
AU2018351059A1 (en) 2020-04-23
NZ763311A (en) 2026-03-27
US11332459B2 (en) 2022-05-17
IL273839A (en) 2020-05-31
PH12020550265A1 (en) 2021-03-01
CN111417394A (zh) 2020-07-14
ZA202002762B (en) 2025-03-26
IL273839B (en) 2022-09-01
EP3697410C0 (en) 2024-12-18
CL2020001020A1 (es) 2020-09-21
SA520411787B1 (ar) 2022-08-29
KR20200074965A (ko) 2020-06-25
MX2020003993A (es) 2020-08-13
EP3697410A4 (en) 2021-08-11
WO2019079578A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
JP7389856B2 (ja) Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物
EP2691399B1 (en) Thiazolopyrimidine compounds
AU2019313441B2 (en) TLR7/8 antagonists and uses thereof
EP3743430B1 (en) Aminopyrrolotriazines as kinase inhibitors
US11332459B2 (en) Benzimidazole derivatives and their uses
EP3400221B1 (en) Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
AU2019382504B2 (en) Cyclic ureas
RS63653B1 (sr) Benzodiazepinski derivati kao inhibitori rsv
IL323942A (en) Sarm1 modulators, preparations, and uses thereof
WO2026022742A1 (en) Cbl-b inhibitor and uses thereof
EA043189B1 (ru) Производные бензимидазола и их применение в качестве ингибиторов trpc6
BR112020007589B1 (pt) Inibidores da atividade de proteína canal receptor de potencial transiente 6 (trpc6) ou seu sal farmaceuticamente aceitável, seu uso, e composição farmacêutica
HK40032254A (en) Benzimidazole derivatives and their uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)